Association of an increased frequency of CD14(+)HLA-DR(lo/neg) monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)

Míreanna Comhchosúla

• The CD14(+)HLA-DR(lo/neg) Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy
  le: Mengos, April E., et al.
  Foilsithe: (2019)
• Systemic immune suppression in glioblastoma: the interplay between CD14(+)HLA-DR(lo/neg) monocytes, tumor factors, and dexamethasone
  le: Gustafson, Michael P., et al.
  Foilsithe: (2010)
• Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses
  le: Laborde, Rebecca R., et al.
  Foilsithe: (2014)
• Immunosuppressive CD14(+)HLA-DR(lo/neg) monocytes are elevated in pancreatic cancer and “primed” by tumor-derived exosomes
  le: Javeed, Naureen, et al.
  Foilsithe: (2016)
• Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients
  le: Cordes, Stefan F, et al.
  Foilsithe: (2013)